Evaluation of the New Laser PHOTOLASE PLV-585nm for the Treatment of Rosacea

NCT ID: NCT03708263

Last Updated: 2022-03-15

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 1 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-08
• Study Completion Date: 2021-09-14

Brief Summary

Rosacea is a frequent dermatological condition, with a chronic and disturbing evolution that is characterized by redness, permanent erythema associated with telangiectasia (visible and permanent dilatation of the small vessels). It frequently affects men and women with fair skin and can have significant psycho-emotional consequences.

To counteract the unaesthetic appearance of redness and eliminate telangiectasia, the use of the laser is proposed to the patient.

This study is a single center prospective, randomized, controlled split face study to compare 532nm KTP laser versus 585 nm PLV Laser in terms of improvement of the symptoms in the treatment of Erythematotelangiectatic Rosacea 20 subjects will receive up to 3 laser treatments at day 0, month 2 and 4 and will be followed at month 6 and 12.

Detailed Description

Adult male and female subjects 18 years of age or older will participate in the study after the objectives, methods, and potential risks of the study have been explained, and after they have signed the informed consent form.

Patients will come to the investigation center for a maximum of 6 visits.

Conditions

Erythematotelangiectatic Rosacea

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

532nm KTP Laser

Cutera® Excel V 532 nm Application of light spots 5 to 7 mm for a pulse duration of 8 to 20 ms and a fluence of 7.4 to 10 J / cm2.

Group Type: ACTIVE_COMPARATOR

Excel V 532nm (KTP) green Laser

Intervention Type: DEVICE

Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization

585 nm yellow laser

PHOTOLASE PLV 585 nm Application of light spots 1.4mm for a pulse duration of 10 to 100 ms and a fluence of 0 to 65 J / cm2.

Group Type: EXPERIMENTAL

PHOTOLASE PLV 585 nm yellow laser

Intervention Type: DEVICE

Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization

Interventions

Excel V 532nm (KTP) green Laser

Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization

Intervention Type: DEVICE

PHOTOLASE PLV 585 nm yellow laser

Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Fitzpatrick Skin Type I - III
• Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrolment and during the entire course of the study.
• Clinical diagnosis of Erythematotelangiectatic Rosacea stade II
• Homogeneous extend and staining telangiectasia in each half face
• Patient never treated with laser for Rosacea
• Patient doesn't wish to use systemic corticosteroids or retinoids; or topical corticosteroids or retinoids on the treated area.
• Patient agreeing to have limited exposure to the sun and use of a protective screen (index 50 or higher) every day of the study and throughout its duration if it takes place from May to September.
• Patient must be able to read, understand and sign the Informed Consent Form
• Patient able to adhere to the program of visits of the study and the other imperatives of the protocol
• Patient accepting to have photographs taken on the face
• Quality of social insurance or social security entitlement

Exclusion Criteria

• Pregnant and/or breastfeeding woman or childbearing age without effective contraception
• Alcohol abuse assessed at the discretion of the investigator
• History of prior laser or light based procedures for any other pathology for the face within 6 months of study participation Fitzpatrick Type IV à VI
• Systemic use of isotretinoin in the 6 months prior to inclusion in the study.
• Topical use of retinoids and / or corticosteroids in the 4 weeks prior to inclusion in the study.
• Patient under photo sensitization treatment
• Patient suffering from significant concurrent illness such as type 1 diabetes, cardiovascular disease, uncontrolled hypertension, neurological disease, lupus erythematosus, scleroderma.
• Patient subject to hypertrophic or abnormal scarring
• Patient presenting or having a malignant tumor or skin cancer in the area to be treated.
• Having a known anticoagulative condition or taking prescription anticoagulation medications.
• Participation to another clinical study involving a laser or drug within three months of inclusion in the study.
• Smoker or former smoker in the 12 months prior to inclusion in the study.
• Patient with excessive tattoos in the area to be treated and / or wishing to tattoo the treated area during the study.
• Patient treated for cancer by chemotherapy or radiotherapy
• Patient with hyper or hypo pigmentation
• Patient unable to understand protocol or give consent
• Legal incapacity (persons deprived of their liberty or under guardianship or curatorship)
• Patient in emergency or in detention
• Clinical follow-up impossible for psychological, family matters, social or geographical reasons

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

Sponsor Role: collaborator

Medical Research Fund of the Tampere University Hospital, Finland

OTHER

Sponsor Role: collaborator

University Hospital, Lille

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Cyril MAIRE, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Lille

Serge MORDON, Pr

Role: STUDY_DIRECTOR

Institut National de la Santé Et de la Recherche Médicale, France

Locations

Hop Claude Huriez Chu Lille

Lille, , France

Countries

France

Other Identifiers

2018-A01904-51

Identifier Type: OTHER

Identifier Source: secondary_id

2017_57

Identifier Type: -

Identifier Source: org_study_id